title: Parotid gland metastasis of a breast cancer.
abstract: Parotid gland metastases from malignant tumors are extremely rare. A 61-year-old woman was diagnosed with an early breast cancer with no expression of oestrogen and progesterone receptors. Five years later the patient presented a tumour in parotid gland. After total parotidectomy, microscopic analysis of the gland demonstrated an invasive duct carcinoma (IDC) with positive expression of oestrogen receptor. The patient was treated with chemotherapy followed by complementary local radiotherapy. Diagnosis of a metastasic tumour in parotid gland poses a challenge. In our case an immunohistochemical study of oestrogen receptor was fundamental to establish a diagnosis.
authors.affiliation: Department of Oncology and Hematology, Hospital Clínico Universitario, Valencia, Spain. japfidalgo@msn.com
authors.forename: J A
authors.initials: JA
authors.lastname: Perez-Fidalgo
authors.forename: I
authors.initials: I
authors.lastname: Chirivella
authors.forename: J
authors.initials: J
authors.lastname: Laforga
authors.forename: J M
authors.initials: JM
authors.lastname: Colio
authors.forename: M D
authors.initials: MD
authors.lastname: Blanes
authors.forename: R
authors.initials: R
authors.lastname: Baydal
authors.forename: S
authors.initials: S
authors.lastname: Roselló
authors.forename: E
authors.initials: E
authors.lastname: De-la-Morena
authors.forename: A
authors.initials: A
authors.lastname: Lluch
mesh_terms: D000077384:Anastrozole; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery; D000069287:Capecitabine; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007150:Immunohistochemistry; D015409:Mastectomy, Radical; D008875:Middle Aged; D009570:Nitriles / Q000008:administration & dosage / Q000627:therapeutic use; D010306:Parotid Gland / Q000473:pathology / Q000601:surgery; D010307:Parotid Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary* / Q000601:surgery; D011960:Receptors, Estrogen / Q000032:analysis; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D011960:Receptors, Estrogen; D014230:Triazoles; D003841:Deoxycytidine; D000077384:Anastrozole; D000069287:Capecitabine; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil